Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Thursday announced promising early data from its Phase 2a trial of SLS009 or tambiciclib ...

SELLAS announced promising Phase 2a trial results for SLS009 in r/r DLBCL, achieving 67% response rate and 83% disease control. SELLAS Life Sciences Group, Inc. announced promising results from a ...

SELLAS Life Sciences CEO Angelos Stergiou says his company is already on the cusp of a finalized leukemia vaccine, but another game-changer – personalized cancer vaccines – could be on the ...

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...